title: Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
authors.affiliation: Liver Unit, Division of Gastroenterology and Hepatology, Hospital Universitario Central de Asturias, Avenida de Roma S/N, 33011, Oviedo, Spain.
authors.forename: Gino S
authors.initials: GS
authors.lastname: Albines
authors.forename: Alicia
authors.initials: A
authors.lastname: Mesa
authors.forename: Nelson
authors.initials: N
authors.lastname: Fuentes-Martínez
authors.forename: Ramón
authors.initials: R
authors.lastname: Pérez
authors.forename: Julieta
authors.initials: J
authors.lastname: Fernández-Molina
authors.forename: Manuel
authors.initials: M
authors.lastname: Rodríguez
authors.forename: María
authors.initials: M
authors.lastname: Varela
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000821:virology*; D008113:Liver Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D012367:RNA, Viral / Q000097:blood; D012720:Severity of Illness Index; D000077157:Sorafenib; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D015415:Biomarkers; D010671:Phenylurea Compounds; D012367:RNA, Viral; D009536:Niacinamide; D000077157:Sorafenib